骨关节炎药物市场 - 依药物类型（黏稠补充剂、非类固醇抗发炎药、镇痛药、皮质类固醇）、给药途径（口服、肠胃外）、解剖学、药物、配销通路和预测2024 - 2032

Osteoarthritis Drugs Market - By Drug Type (Viscosupplementation Agents, NSAIDs, Analgesics, Corticosteroids), By Route of Administration (Oral, Parenteral), By Anatomy, By Medication, By Distribution Channel & Forecast 2024 - 2032

出版日期: 2024年03月19日 | 出版商:

Global Market Insights Inc. | 英文 260 Pages | 商品交期: 2-3个工作天内

价格

简介目录

骨关节炎药物市场规模预计从2024 年到2032 年将以6.9% 的复合年增长率扩大。需求。根据澳洲统计局的数据，2022年，澳洲约有370万人患有关节炎。

药物开发的重大突破，包括新疗法和生物製剂的推出，正在促进产业创新。医疗保健专业人员和患者对骨关节炎早期诊断和治疗重要性的认识不断提高，也增加了骨关节炎药物的吸引力。老年人口的不断扩大，加上肥胖相关骨关节炎负担的日益加重，正在为产品开发创造大量机会。越来越多的改善医疗保健服务和骨关节炎治疗报销政策的措施将进一步促进市场的发展。

骨关节炎药物市场分为药物类型、给药途径、解剖学、药物、配销通路和地区。

就药物类型而言，由于骨关节炎患者对止痛药物的需求增加，2024年至2032年间止痛药市场规模将以7.1%的成长率成长。骨关节炎相关疼痛的普遍存在推动了对有效镇痛药物的需求，以控制症状并改善患者的生活品质。非处方（OTC）镇痛药和处方药的出现，加上药物配方和给药方法的进步，正在推动该细分市场的成长。

根据给药途径，由于口服药物的便利性和患者的广泛接受性，2024年至2032年口服骨关节炎药物行业的复合年增长率预计为6.7%。与其他途径相比，口服药物给药方便，患者依从性较高。包括片剂、胶囊和液体在内的多种口服製剂的可用性也为剂量和治疗选择提供了灵活性。

从地区来看，由于人口迅速老化以及生活型态改变导致骨关节炎盛行率不断增加，预计2024年至2032年亚太地区骨关节炎药物产业的年增率将达到7.5%。亚太地区不断增长的医疗保健支出正在改善医疗保健服务的可近性，并提高人们对骨关节炎治疗方案的认识。新疗法的引入、药物开发的进步以及政府为解决肌肉骨骼疾病负担而采取的倡议也有利于区域市场的扩张。

主要动向：按地区
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 11 章：公司简介

Anika Therapeutics
Assertio Holdings, Inc.
Bayer AG
Bioventus
Ferring Pharmaceuticals Inc.
GSK plc
Novartis AG
Pacira Pharmaceuticals, Inc
Pfizer Inc
Sanofi SA
Zimmer Biomet Holdings, Inc.

简介目录

Product Code: 8580

Osteoarthritis Drugs Market size is projected to expand at 6.9% CAGR from 2024 to 2032. The increasing prevalence of osteoarthritis due to aging population and sedentary lifestyles is fueling the demand for effective treatment options. As per the Australian Bureau of Statistics, in 2022, around 3.7 million people suffered from arthritis in Australia.

Significant breakthroughs in drug development, including the introduction of novel therapies and biologics are promoting innovations in the industry. The rising awareness about the importance of early diagnosis and treatment of osteoarthritis among healthcare professionals and patients is also increasing the appeal of osteoarthritis drugs. The expanding geriatric population, coupled with the growing burden of obesity-related osteoarthritis is creating numerous opportunities for product development. The growing initiatives to improve access to healthcare services and reimbursement policies for osteoarthritis treatments will further compliment the market progression.

The osteoarthritis drugs market is segregated into drug type, route of administration, anatomy, medication, distribution channel, and region.

In terms of drug type, the market size from the analgesics segment will grow at 7.1% growth rate between 2024 and 2032, due to the higher demand for pain relief medications among osteoarthritis patients. The prevalence of osteoarthritis-related pain is driving the need for effective analgesic drugs to manage symptoms and improve quality of life of patients. The availability of over-the-counter (OTC) analgesics and prescription medications, coupled with advancements in drug formulations and delivery methods is driving the segment growth.

Based on route of administration, the osteoarthritis drugs industry from the oral segment is slated to depict 6.7% CAGR from 2024 to 2032, on account of the convenience and widespread acceptance of oral medications among patients. Oral drugs offer ease of administration and greater patient compliance compared to other routes. The availability of a wide range of oral formulations, including tablets, capsules, and liquids is also providing flexibility in dosing and treatment options.

Regionally, the Asia Pacific osteoarthritis drugs industry is projected to expand at 7.5% CGR from 2024 to 2032, owing to the rapidly aging population and increasing prevalence of osteoarthritis due to lifestyle changes. The rising healthcare expenditure across APAC is improving access to healthcare services and expanding awareness about osteoarthritis treatment options. The introduction of novel therapies, advancements in drug development, and the launch of government initiatives to address the burden of musculoskeletal diseases are also favoring the regional market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing geriatric population
  - 3.2.1.2 Increasing research & development activities and funding for osteoarthritis therapeutics
  - 3.2.1.3 High prevalence of osteoarthritis
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects associated with drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Million)

5.1 Key trends
5.2 Viscosupplementation agents
5.3 Nonsteroidal anti-inflammatory drugs
- 5.3.1 Naproxen
- 5.3.2 Aspirin
- 5.3.3 Diclofenac
- 5.3.4 Ibuprofen
- 5.3.5 Celecoxib
- 5.3.6 Meloxicam
- 5.3.7 Piroxicam
- 5.3.8 Ketoprofen
- 5.3.9 Other NSAIDs
5.4 Analgesics
- 5.4.1 Duloxetine
- 5.4.2 Acetaminophen
5.5 Corticosteroids
5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

6.1 Key trends
6.2 Oral
6.3 Parenteral
6.4 Topical

Chapter 7 Market Estimates and Forecast, By Anatomy, 2018 - 2032 ($ Million)

7.1 Key trends
7.2 Ankle osteoarthritis
7.3 Hip osteoarthritis
7.4 Knee osteoarthritis
7.5 Shoulder osteoarthritis
7.6 Other anatomies

Chapter 8 Market Estimates and Forecast, By Medication, 2018 - 2032 ($ Million)

8.1 Key trends
8.2 Prescription drugs
8.3 Over-the-counter drugs

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa